Drug Profile
Pegfilgrastim biosimilar - Biocon/Viatris
Alternative Names: Fulphila; MYL 1401H; PEG G CSF; pegfilgrastim-jmdbLatest Information Update: 03 Aug 2023
Price :
$50
*
At a glance
- Originator Biocon
- Developer Biocon; Viatris Inc
- Class Antineoplastics; Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor receptor agonists; Granulocyte colony-stimulating factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Chemotherapy induced febrile neutropenia; Febrile neutropenia
- Phase III Autoimmune disorders; Cancer
Most Recent Events
- 03 Aug 2023 Pegfilgrastim biosimilar is registered for Febrile neutropenia in New Zealand (Biocon website, August 2023)
- 03 Aug 2023 Launched for Chemotherapy induced febrile neutropenia in Singapore, Poland, Netherlands, Austria, France, Finland, Malaysia, Switzerland, Sweden, Germany, Israel (SC)
- 03 Aug 2023 Registered for Chemotherapy induced febrile neutropenia in New Zealand (SC) (Biocon website, August 2023)